Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 52
- Registration Number
- NCT02788773
- Locations
- 🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇨🇦London Regional Cancer Program, London, Ontario, Canada
🇨🇦Odette Cancer Centre, Toronto, Ontario, Canada
Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers
- Conditions
- Interventions
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 48
- Registration Number
- NCT02777710
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷IUCT-oncopole, Toulouse, France
Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Moshe Ornstein
- Target Recruit Count
- 29
- Registration Number
- NCT02762006
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT02754856
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 313
- Registration Number
- NCT02740985
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
A Study of LY2510924 and Durvalumab in Participants With Solid Tumors
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 9
- Registration Number
- NCT02737072
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 73
- Registration Number
- NCT02735239
- Locations
- 🇬🇧
Research Facility, Southampton, United Kingdom
A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 37
- Registration Number
- NCT02734160
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇮🇹Ospedale Policlinico Giambattista Rossi, Borgo Roma, Verona, Italy
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 106
- Registration Number
- NCT02733042
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Jefferson Medical Oncology Associates, Philadelphia, Pennsylvania, United States
🇫🇷Centre Hospitalier Universitaire d'Avicennes, Bobigny Cedex, France
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
- Conditions
- Stage III Ovarian Cancer AJCC v6 and v7Stage III Primary Peritoneal Cancer AJCC v7Stage IIIA Fallopian Tube Cancer AJCC v7Stage IIIB Fallopian Tube Cancer AJCC v7Stage IV Ovarian Cancer AJCC v6 and v7Stage IIIC Fallopian Tube Cancer AJCC v7Stage IIIC Primary Peritoneal Cancer AJCC v7Stage IV Fallopian Tube Cancer AJCC v6 and v7Stage IV Primary Peritoneal Cancer AJCC v7Stage III Fallopian Tube Cancer AJCC v7
- Interventions
- First Posted Date
- 2016-04-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT02726997
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.